NOVAVAX INC NOVAVAX ORD SHS 

$11.9
835
-$2.75-18.8% Friday 18:12

統計

當日最高
14.7
當日最低
13.18
52週最高
27
52週最低
3.53
成交量
199,351
平均成交量
157,217
市值
-
市盈率
-
股息收益率
-
股息
-

即將到來

收益

6Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-3.46
-1.75
-0.04
1.67
預期每股收益
-0.903333
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 0A3S.LSE 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Show more...
首席執行官
Mr. John Charles Jacobs M.B.A.
員工
1543
國家
US
ISIN
US6700024010

上市公司